1. Home
  2. STELLA PHARMA NEWS
  3. Information
STELLA PHARMA NEWS
Information
December 25th, 2023

Orphan Drug designation for Borofalan (10B) (SPM-011) as treatment of Cutaneous Angiosarcoma

Angiosarcoma is a kind of cancer that is derived from vascular endothelial cell……

READ MORE

December 6th, 2023

Encounter with Director of Cancer Research Center of Lyon, and Team of Centre Léon Bérard at French Embassy

Business France Japan Office of the French Embassy in Japan engages in building……

READ MORE

September 29th, 2022

Groundbreaking Ceremony for the Hainan BNCT Center

On 25th September, the Groundbreaking Ceremony for the Boao BNCT center has tak……

READ MORE

September 27th, 2022

Stella Pharma Presented at Side Events of the 66th IAEA General Conference

The 66th International Atomic Energy Agency (IAEA) General Conference is being ……

READ MORE

April 7th, 2022

Stella Pharma Corporation was nominated as a finalist of the Informa Pharma Intelligence Awards Japan 2022

Informa Pharma Intelligence has announced that Stella Pharma is a nominee f……

READ MORE

February 18th, 2022

“Destroying Cancer with Boron and Neutrons” will be on NHK WORLD-JAPAN

Japan's public media organization NHK (Japan Broadcasting Corporation) will bro……

READ MORE

October 21st, 2021

Interview published on Science Japan, online magazine| Japan’s “Fifth Cancer Treatment,” BNCT, Finally Off the Ground

Here is a featured story on BNCT (Boron Neutron Capture Therapy) boron drug dev……

READ MORE

June 23rd, 2021

The phase II study of recurrent glioblastoma in Japan has published in “Neuro-Oncology Advances”

The title is “Accelerator-based BNCT for patients with recurrent glioblastoma: ……

READ MORE

December 9th, 2020

The phase II study of recurrent or locally advanced head and neck cancer in Japan has published in “Radiotherapy and Oncology”

The title is "Boron neutron capture therapy using cyclotron-based epithermal ne……

READ MORE